Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| FRACTYL HEALTH, INC.GUTS · Entity 6700 | Chief Financial Officer | June 08, 2026 | June 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
FRACTYL HEALTH, INC.
Report date June 08, 2026 · Filed June 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 20,000 |
Reported balance
After 2026-06-08 transaction · row 1
1 source rowRow 1 · 2026-06-08 · Purchase · Acquired 20,000 · Balance 20,000 F1: Open market purchase. F2: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.6844 to $0.6896, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: Open market purchase.
F2: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.6844 to $0.6896, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 08, 2026 Filed Jun 9, 2026 22:55 UTC | FRACTYL HEALTH, INC. GUTS · Entity 6700 | PurchaseCommon Stock | 20,000 | $0.69 | $13,708.00 |
DisclosureSEC source: 0001193125-26-264430 · ownership.xml · nonDerivative · entry 1 Smith Weber Lara · CIK 0002105051 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 F1 · kind: Open market purchase. F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.6844 to $0.6896, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| January 12, 2026 Filed Jan 14, 2026 21:30 UTC | FRACTYL HEALTH, INC. GUTS · Entity 6700 | GrantStock Option · Derivative | 1,036,800 | $0.00 Strike: $2.00 | $0.00 |
DisclosureSEC source: 0001193125-26-012975 · ownership.xml · derivative · entry 1 Smith Weber Lara · CIK 0002105051 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,036,800 Underlying: Common Stock · 1,036,800 shares Expires 2036-01-11 F1 · derivative.exercise_date: The stock option vests and becomes exercisable as to 25% of the shares subject to the option on January 12, 2027, with the remaining 75% of the underlying shares vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service with the Company as of each such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.